Status:
TERMINATED
A Study of ProQuad™ in Healthy Children in Korea (V221-023)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Measles
Mumps
Eligibility:
All Genders
12-23 years
Phase:
PHASE3
Brief Summary
This study will compare ProQuad™ and concomitant administration of M-M-R™ II and Varivax™ with respect to immunogenicity, safety and tolerability. The primary hypothesis to be tested is that the antib...
Eligibility Criteria
Inclusion
- Subject is in good health
- Subject has a negative clinical history for measles, mumps, rubella, varicella and zoster
Exclusion
- Subject has previously received measles, mumps, rubella and/or varicella vaccine, either alone or in any combination
- Subject has any congenital or acquired immune deficiency, neoplastic disease or depressed immunity
- Subject has a history of seizure disorder
- Subject had exposure to measles, mumps, rubella, varicella and/or zoster in the last 4 weeks
- Subject has received an inactivated vaccine within the past 14 days
- Subject has received a live vaccine within the past 30 days
- Subject has received immune globulin within the past 5 months
- Subject has a recent history of fever (within the last 72 hours)
Key Trial Info
Start Date :
February 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2008
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00839917
Start Date
February 1 2008
End Date
May 1 2008
Last Update
April 12 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.